Personalized medicine (PM) is defined as "a form of medicine that uses information about a person's genes, proteins, and environment to prevent, diagnose, and treat disease." The promise of PM has been upon us for years. The suite of clinical applications of PM in cancer is broad, encompassing screening, diagnosis, prognosis, prediction of treatment efficacy, patient follow-up after surgery for early detection of recurrence, and the stratification of patients into cancer subgroup categories, allowing for individualized therapy. PM aims to eliminate the "one-size fits all" model of medicine, which has centered on reaction to disease based on average responses to care. By dividing patients into unique cancer subgroups, treatment and follow-up can be tailored for each individual according to disease aggressiveness and the ability to respond to a certain treatment. PM is also shifting the emphasis of patient management from primary patient care to prevention and early intervention for high-risk individuals. In addition to classic single molecular markers, high-throughput approaches can be used for PM including whole genome sequencing, single nucleotide polymorphism analysis, microarray analysis, and mass spectrometry. A common trend among these tools is their ability to analyze many targets simultaneously, thus increasing the sensitivity, specificity, and accuracy of biomarker discovery.
Introduction
The field of medicine has seen many new advances in the last several decades. With the completion of the human genome project [1] , an enormous amount of new information has been gained about the human genome and the genetic variations between individuals. Added to this is the emergence of new technologies for global genomic analysis, including high-throughput sequencing, single nucleotide polymorphism (SNP) genotyping, and transcript profiling. The construction of haplotype maps of the genome [2, 3] is now allowing us to view DNA in a much bigger picture than ever before. This, coupled with enormous advances in computer systems and bioinformatics, has resulted in a revolutionary shift in medical care to the era of personalized medicine (PM).
PM is defined by the United States National Cancer Institute as "a form of medicine that uses information about a person's genes, proteins, and environment to prevent, diagnose, and treat disease." The promise of PM has been upon us for some years, and is rapidly gaining momentum. The concept of PM is to utilize clinical, genomic, transcriptomic, proteomic, and other information sources to plot the optimal course for an individual in terms of disease risk assessment, prevention, treatment, or palliation. Thus, PM aims to eliminate the "one-size fits all" model of medicine, which has mainly centered on reaction to a disease (treating the symptoms) based on average responses to care, by shifting the emphasis of patient care to cancer prevention and early intervention for high-risk individuals [4, 5] . Moreover, understanding the molecular profiles of individuals and how these can cause variations in disease susceptibility, symptoms, progression, and responses to treatment will lead to tailoring medical care to fit each individual patient [6] [7] [8] .
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Copyright © 2010 American Association for Cancer Research experience markedly different disease courses, to the molecular scale, which offers a highly detailed, global perspective of the disease process and promises superior performance over traditional classifications [25] [26] [27] [28] . Molecular analyses at the protein, DNA, RNA, or microRNA (miRNA) levels, can contribute to the identification of novel tumour subclasses, each with unique prognostic outcome or response to treatment, that could not be identified by traditional morphological methods [10] . Recently, molecular classification has been used to identify unique subclasses of cancers including acute myeloid leukemia (AML) [29, 30] , glioblastoma [31] , breast cancer [32, 33] , renal cell carcinoma [34, 35] , and to differentiate between Burkitt's lymphoma and diffuse B-cell lymphoma [36] . Sub-classification of cancers into unique molecular groups with distinct prognosis or treatment options will significantly improve patient management.
Targeted Therapy and Predictive Markers for Treatment Efficiency
The ultimate goal of PM is to define disease at the molecular level so that therapy can be directed at the right population of patients (the predicted "responders"). Thus, elucidating the molecular differences between individuals will have an impact on how new treatments are developed and would be of great benefit to pharmaceutical companies looking to market new cancer drugs. It is now known that even in individuals with similar clinical phenotypes (clinical manifestations and pathological type), drug therapy is usually only effective in a fraction of those treated, suggesting that other differences account for individual drug responses [7] . Being able to predict which patients will benefit from a drug would promote a shift to identify alternative therapies to improve outcomes in the predicted "non-responders," in turn reducing the administration of costly and potentially toxic treatments to them. Furthermore, clinical trials of response at all [49, 50] by altering the pharmacokinetics of drug metabolism and distribution [48] , and could also account for the common occurrence of adverse drug reactions [51] . Thus, these polymorphisms could be used to predict optimal drug dosage, minimize harmful side effects, reduce the costs of "trial-and-error dosing," and ensure more successful outcomes [50] .
In familial breast cancer, for example, genetic variations in CYP2D6 that confer "poor- targets. This multi-parametric approach is likely to improve sensitivity, specificity, and accuracy of new biomarkers [35] . In addition to acceleration of biomarker discovery, high-throughput analysis allows a better understanding of the "cross-talk" or interaction between different molecules in the pathogenesis of cancer. Below, we will highlight some of the commonly used techniques for global analysis.
High-Throughput Whole Genome Sequencing
The completion of the human genome project has motivated the development of "nextgeneration sequencing" technologies [61] . High-throughput analyzers from Roche (454 Genome Analyzer), Life Technologies (SOLiD analyzer), and Illumina (Genome Analyzer IIe and HiSeq
2000)
now make it possible to analyze millions of nucleotides at once, at a lower cost compared to the traditional Sanger method. These analyzers use pyrosequencing [62] or sequencing by ligation [61] , rather than the traditional Sanger end-chain termination method. Table 2 summarizes the commonly used high-throughput sequencers with their features and applications for PM. Advantages of high-throughput sequencing include the capacity to perform multiplex reactions, reduced operating costs, and very fast acquisition of data.
Next-generation sequencing is now being used for global analysis of the genome.
Previously, some cancer alleles could not be detected by Sanger sequencing because they were present in extremely low levels in cells. Now, the use of "deep sequencing" (extensive repeated coverage of the sequence of interest) [63] and paired-end sequencing [64] has made their identification possible, thus expanding our understanding of the cancer genome. Laser capture microdissection [65] has also been useful for isolating and enriching cancer cell DNA and RNA obtained from a tissue sample, which can then be used for targeted sequencing. These methods enabled the identification of novel mutations, rearrangements, and other genomic alterations [66] [67] [68] that lead to tumorigenesis in AML [69, 70] , CML [67] , and other cancers [71] [72] [73] [74] .
Methods for high-throughput sequencing continue to evolve. Biotechnology companies such as Complete Genomics, Helicos, and Pacific Biosciences are now working on "third generation sequencing" methods, which are expected to further reduce cost, increase accuracy and length of reads, and provide even higher-throughput analysis of genomes [61, 75] . As the reality of faster and cheaper high-throughput analyses is becoming closer, several biotechnology companies are racing to commercialize full genome sequencing, which is expected within the next few years [68, 75] . Although currently too expensive (~$48,000 USD for a full genome by Illumina), it is estimated that the era of the "$1000" genome is fast-approaching [76] .
There is no doubt that whole genome sequencing is a powerful tool for digging deep into the genetic code to look for influences on disease; however, with such a tool comes the challenge of determining what information is most important for analysis and interpretation, and this is one 
SNP Analysis and Haplotype Mapping
The human genome is estimated to have over 30 million SNPs, which are essentially the "fingerprints" of our genetic code [77, 78] . Some of these have been thoroughly characterized by the International Haplotype Mapping Project [2, 3] in various populations and made publically available [79] . These databases have provided the necessary tools for researchers to discover associations between disease risk and common SNPs [80] . The advent of commercially available microarrays (SNP chips) [81] , has resulted in a shift from studying disease by linkage analysis, to using genome-wide association studies [82] . SNP arrays employ allele-specific oligonucleotide probes that produce a fluorescent signal when a specific allele of a SNP is present, and are capable of analyzing up to one million SNPs in a single sample [83, 84] .
Alternatively, SNP haplotypes, rather than single SNPs, can be analyzed. SNP arrays can also be used for screening for common features of cancer genomes like allelic imbalance, copy number variation, or loss of heterozygosity. SNP arrays have been used extensively to assess various aspects of cancer, including risk assessment [85] [86] [87] ; prognosis [88] ; survival [89] ; response to therapy [90] ; and progression and metastasis [91] [92] [93] .
Microarray Analysis
Microarrays are widely used for global analysis of gene expression in cancer because they are cost-effective and high-throughput [94] . Microarrays are chips with immobilized capture molecules (such as oligonucleotides or cDNAs), that serve as probes for binding fluorescently- Newer microarray platforms, such as miRNA microarrays are also showing encouraging preliminary data for the potential use as cancer biomarkers [108] [109] [110] [111] [112] [113] . MiRNA signatures have been used to stratify patients into prognostic cohorts and treatment subgroups. Finally, microarrays can be used to assess epigenetic changes in cancer (DNA methylation, histone acetylation, serine phosphorylation), which are implicated in tumorigenesis, and can be used to classify cancers and direct patient management [114] .
Proteomics by Mass Spectrometry
Changes in the protein profiles of cancer cells can be important for determining new diagnostic biomarkers, and may also aid in the classification of tumours into unique subtypes [115] . Proteomic analysis can be advantageous over mRNA measurements as proteins are the final effector molecules and their levels do not always correlate with mRNA levels due to posttranscriptional modifications [116] . 
PM in the clinic: Challenges and controversies
As we move into the era of PM, several challenges have to be addressed. The first is to establish a significant clinical utility that is superior to our existing parameters, and that will lead to a "real" improvement in cancer patient care. This requires a team approach, with collaborative efforts between clinicians, research scientists, computer experts, and biostatisticians, to achieve a clinically meaningful outcome. Full transparency in reporting results (especially the negative ones) should be emphasized to avoid selection bias for positive results reporting [35] . It also has to be noted in this regard that statistically significant results in a research setting are not always equivalent to clinically significant results. Prospective trials on large patient cohorts are needed to solidify the clinical utility of new tests being offered to cancer patients. Care must be taken when interpreting published results due to the heterogeneity of the analyzed material, which can be obtained from tissues, cell lines, and biological fluids, and when comparing different histological types, stages and grades of tumors.
Another important issue is the need for standardization of testing. Standardization encompasses several aspects including the type of specimen to be analyzed, the appropriate methods of specimen collection and storage, the choice of the target genes/proteins to be tested, the platform to be used, optimal experimental conditions, and the clinical interpretation of tests One of the most important considerations will be the higher cost of incorporating new, advanced technologies that will provide more detailed predictive and prognostic information about each individual patient. Setting up the infrastructure for PM will require significant spending. Prices are, however, becoming much more affordable compared to earlier years, as technology becomes more widespread. Following an initial capital investment, additional running costs will become much less. The increased cost of these advanced diagnostic systems will be partially compensated for by savings in patient care cost, such as reduced courses of unnecessary chemotherapy or radiotherapy, and reduced hospital stays.
Ethical issues, including who will have access to this new detailed information, especially those at risk of developing cancer, should be adequately addressed. Individuals should be free to accept or decline susceptibility testing. The access for insurance companies, other family members, employers, and other agents, will need to be clearly stated and new laws may have to be passed to ensure fair treatment, protection, and privacy of the tested individuals. Misuse of genetic information could take place at the expense of those tested. Patients with known risks for developing cancer, those who are expected to have poor outcomes, or those who will not respond well to treatments, may be discriminated against or denied employment opportunities or health insurance coverage. Individuals who are expected to not respond to treatment may also be denied certain medications. Also, the cost of targeted therapies is high. In this case, although 
Copyright © 2010 American Association for Cancer Research genetic testing may indicate one would receive benefits from a certain drug, they may have limited access due to wealth or insurance status. In this case, PM will add to the problem of socioeconomic divisions. Furthermore, genetic testing may reveal traits for other serious illnesses (regardless of whether an individual chooses to find out about them or not), which may also affect how they are treated by others. Good policy decisions will be crucial to reap the benefits of PM [142] . Luckily, in the USA, laws are already in place to protect patients from these types of issues [8] .
Personalized medicine: Fantasy or reality?
The introduction of the concept of PM initially created a lot of promise in the scientific community. There was optimism for an imminent revolution in our medical practice whereby a molecular "fingerprint" for each cancer patient would replace the clinicopathological designation system, and would provide many pieces of information related to treatment simultaneously. This was, however, followed by a dormant period when promising research results did not cross the bridge to be adopted into clinical applications. One important reason for this is that the new classifiers created new "categories" of patients for which the clinical significance was unknown.
One famous example of this is the basal-like phenotype of breast cancer that was created by microarray analysis [143] . There are important reasons as to why there has not been a rapid change in the approach to cancer with the introduction of PM. The process of developing a tumor marker for "clinical" use is a tedious and multi-step process requiring extensive testing, optimization, validation, and establishment of usefulness above other currently used methods [57] .
A Future Prospective
It is clear from recent literature that the concept of PM will have a significant impact on medical practice and is gradually being included as an integral component of our cancer management plans. It will inevitably result in more effective treatment and fewer side effects for patients, and will induce a proactive and participatory role of the patient in their own healthcare decisions. Patients will have the incentive to engage in lifestyle choices and health maintenance to compensate for their genetic susceptibilities.
Before the era of PM, cancer diagnosis, prognosis, and subsequent treatment decisions were based on histopathologic parameters including the tissue of origin and the stage and grade of the tumour. Experience has shown morphological classification to be deficient in many aspects and that patients with the same histopathologic diagnosis can have unexplained variable outcomes. Individual molecular markers have been slowly added to ameliorate the accuracy of predicting prognosis and prediction of treatment efficiency. We now witness the accumulation of enormous amounts of genomic data generated by high-throughput analyses, and augmented by tremendous advances in computer analytical systems. PM is a revolutionary concept that challenges our traditional classification and management of cancer. Although very appealing, it is unlikely that it will completely replace traditional approaches, at least in the near future. It will be essential to confirm the validity of new biomarkers generated by PM technologies using prospective clinical trials in independent patient cohorts. This will be an ongoing process that is expected to extend for many years to come.
The introduction of PM requires a very big initial investment, but with it comes the promise of a rewarding and cost-effective future for medical practice. Figure 2 shows one possible future scenario where molecular analysis can be incorporated with the various steps of 
